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Clinics and pathology 
Disease 
Acute megakaryoblastic leukemia (AMKL) 
Note 
Acute megakaryoblastic leukemia (AMKL) was so far 
divided into three subgroups: AMKL arising in patients 
with Down syndrome (DS-AMKL), AMKL with a 
t(1;22)(p13;q13) giving rise of a 5' OTT - 3' MAL 
fusion gene, and "other" AMLKs, i.e. non Down 
syndrome / non t(1;22). 
Two new categories have recently been individualized 
from the subgroup "non Down syndrome / non t(1;22)": 
the inv(16)(p13q24) CBFA2T3/GLIS2, and the 
t(11;12)(p15;p13) NUP98/KDM5A (Gruber et al., 
2012; Thiollier et al., 2012). 
Epidemiology 
Fourteen patients with data on sex and age are 
available; median age at diagnosis was 1 year - 1 year 4 
months (range 6 months - 4 years 7 months).  
The inv(16)(p13q24) CBFA2T3/GLIS2 was found in 
about 30% of non-Down syndrome pediatric AMKL 
cases (in 13 of 48 cases in Gruber et al., 2012, and 7 of 
22 cases in Thiollier et al., 2012. So far, none of the 36 
adult AMKL cases under study contained the chimeric 
transcript. 
One patient had a Down syndrome (case 
SJAMLM7018 in Gruber et al., 2012), which shows 
that DS-AMKL and inv(16)-AMLK categories are not 
mutually exclusive. 
Prognosis 
Subgroup of patients with a significantly worse overall 
survival at 5 years as compared to patients with AMKL 
that lacked this chimeric transcript (28% versus 42% in 
Gruber et al., 2012); fusion associated with treatmnt-
refractory disease (Thiollier et al., 2012). 
Cytogenetics 
Cytogenetics morphological 
This inversion of chromosome 16 is cryptic. The 
CBFA2T3/GLIS2 chimeric gene resulted from simple 
balanced inversions in three cases and from a complex 
rearrangement in one case (Gruber et al., 2012). A 
complex karyotype was found in 8 of the 12 cases with
data on chromosomes; 2 remaining cases exhibited an 
apparently normal karyotype (Gruber et al., 2012). 





Kruppel-like zinc-finger protein. Transcription factor; 
repressor of the Hedgehog signaling pathway; represso  
of the Wnt signaling pathway. GLIS2 has also been 
reported to localize to the primary cilium. A mutation 
GLIS2 has been linked to the development of 
nephronophthisis. Glis2 may act as a repressor of 
epithelial-mesenchymal transition (EMT) and EMT-





Member of the "ETO" family. Functions as a 
transcriptional repressor via interaction with 
corepressor complexes; do not directly bind DNA, but 
interacts with transcription factors such as BCL6, 
PLZF, GFI1, ZNF651 and ZNF652 (Kumar et al., 
2010). 
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5' CBFA2T3 - 3' GLIS2. Fusion between exon 10 of 
CBFA2T3 and exon 3 of GLIS2 in 6 cases (Gruber et 
al., 2012); fusion between exon 11 of CBFA2T3 and 
exon 3 of GLIS2 in 1 case (Thiollier et al., 2012); 
fusion between exon 11 of CBFA2T3 and exon 1 of 
GLIS2 in 1 case (Gruber et al., 2012). 
Fusion protein 
Description 
Retains the three CBFA2T3 N-terminal nervy 
homology regions (NHR) that mediate protein 
interactions and the five GLIS2 C-terminal domains 
(ZnF) responsible for interaction with DNA and 
transactivation. The MYND (myeloid, nervy, and Deaf-
1 domain, class of zinc finger domain reported to 
interact with the N-CoR repressor complex) domain of 
CBFA2T3 is lost. 
Oncogenesis 
This fusion between two transcriptional regulators 
results in aberrant expression of genes controlled either 
by CBFA2T3 or GLIS2 (Thiollier et al., 2012).  
There is an homogenous gene expression signature 
including a strong expression of CD56. Among the 
differentially regulated genes are known targets of the 
Hedgehog pathway including BMP2, BMP4, GATA3, 
and CCND2. CBFA2T3/GLIS2 induces BMP 
signaling. Hedgehog and JAK-STAT pathways are 
significantly upregulated (Gruber et al., 2012; Thiollier 
et al., 2012). CBFA2T3/GLIS2 cells demonstrated  
enhanced self-renewal in vitro (Gruber et al., 2012). 
Aurora A kinase (AURKA) inhibitors can induce 
differentiation and inhibits proliferation of AMKL 
blasts (Thiollier et al., 2012). 
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